Get started
Markets Australia Stocks Health Technology Pharmaceuticals: Major

PYC THERAPEUTICS LIMITED PYC

PYCASX
PYC
PYC THERAPEUTICS LIMITEDASX
See more on advanced chartSee more on advanced chart
 
No trades
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
See more on advanced chartSee more on advanced chart
Overview
News Ideas Financials Technicals Forecast

PYC chart

Ideas

ASX:PYC - PYC Therapeutics Ltd - a unique opportunity?
PYC
, 1WLong
PYC: ASX:PYC - PYC Therapeutics Ltd - a unique opportunity?
Updated 

ASX:PYC PYC is dedicated to changing the lives of patients with rare genetic diseases – a unique opportunity in drug development Very powerful rounding bottom formation, manage the multiyear high and closed above that. Manage to close above the Jan 2010 high, close to 127 months. Given the massive run close to 3X in last one year. Downside -...

Technicals

Analyst rating

Financials

Valuation
Enterprise Value/EBITDA, TTM —
Enterprise Value, FQ —
Market Cap — Basic —
Number of Employees —
Number of Shareholders —
Price/Earnings, TTM —
Price/Revenue, TTM —
Price/Book Ratio, FY —
Price/Sales Ratio, FY —
Balance Sheet
Current Ratio, FQ —
Debt to Equity, FQ —
Net Debt, FQ —
Quick Ratio, FQ —
Total Assets, FQ —
Total Debt, FQ —
Operating Metrics
Return on Assets, TTM —
Return on Equity, TTM —
Return on Invested Capital, TTM —
Revenue per Employee, TTM —
Price History
Average Volume (10 day) —
Beta - 1 Year —
Price - 52 Week High —
Price - 52 Week Low —
Dividends
Dividends Paid, FY —
Dividends per Share, FY —
Expected Annual Dividends —
Dividends Yield —
Margins}
Net Margin, TTM —
Gross Margin, TTM —
Operating Margin, TTM —
Pretax Margin, TTM —
Income Statement
Basic EPS, Net Income —
Earnings per Share, Basic, TTM —
EBITDA, TTM —
Gross Profit, FY —
Last Annual EPS —
Last Annual Revenue, FY —
Net Income, FY —
Total Revenue, FY —
Free Cash Flow, TTM —
More financials

Profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. It develops intracellular biological therapeutics including its own preclinical oncology payloads, using its proprietary cell Functional Penetrating Phylomers. The company was founded by Richmond Miles Hopkins and Paul Michael Watt on October 9, 2001 and is headquartered in Nedlands, Australia.

News flow

More news